Factors associated with the uric acid-lowering effects of sodium-glucose cotransporter-2 inhibition in patients with type 2 diabetes: Insights from the randomized PROTECT trial

Yuichi Saito has received honoraria from Daiichi Sankyo. Atsushi Tanaka has received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline, Takeda, Bristol Myers Squibb and Novo Nordisk. Takumi Imai has received lecture fees from JCR Pharmaceuticals and Kyowa Kirin, and outsourcing fees from the Organization for Clinical Medicine Promotion. Shin-Ichiro Miura has received honoraria from Otsuka Pharmaceutical Co. Ltd, Novartis Pharm., Daiichi Sankyo Co. Ltd, Bayer Yakuhin Ltd and Boehringer-Ingelheim, research grants from OMRON Co., SOMPO Japan and MSD, and scholarships from Otsuka Pharmaceutical Co., Ltd, Boehringer Ingelheim, Daiichi Sankyo Co. Ltd, Sumitomo Pharm., Takeda Pharm. Co. Ltd, Abbott, Boston Scientific, MSD, Bayer Yakuhin Ltd and GM Medical Co. Ltd. Masayoshi Ajioka has received honoraria from Otsuka Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical and Eli Lilly. Kazuhisa Kodama has received honoraria from Otsuka, Novartis and Abbott Medical Japan. Yoshio Kobayashi has received honoraria from Boehringer Ingelheim, Mitsubishi Tanabe, Daiichi Sankyo, Otsuka, Ono, Kowa, Bayer, Novo Nordisk, Novartis, AstraZeneca, Astellas and MSD, and research grants from Astellas, Boehringer Ingelheim and Daiichi Sankyo. Koichi Node has received honoraria from Boehringer Ingelheim, Mitsubishi Tanabe, Teijin, Daiichi Sankyo, Otsuka, Ono, Mochida, Kowa, Bayer, Novo Nordisk, Novartis, Eli Lilly, AstraZeneca, Astellas and MSD, research grants from Asahi Kasei, Astellas, Mitsubishi Tanabe, Teijin, Boehringer Ingelheim, Eli Lilly, Novartis, Fuji and Mochida, and scholarships from Daiichi Sankyo, Mitsubishi Tanabe, Teijin, Medtronic and Bayer. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15368. The data are available upon reasonable request from researchers who submit a detailed proposal outlining their intended use of the data and after approval by the principal investigators and the steering committee of the PROTECT study. Inquiries are to be addressed to the corresponding author (or study secretariat: substudy_protect@clin-med.org). Supplementary Figure S1. Study flow. FAS, full analysis set; SUA serum uric acid. Supplementary Figure S2. Subgroup analyses of between-group differences in changes in SUA levels from baseline to the 24-month follow-up. ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, haemoglobinhemoglobin A1c; SUA, serum uric acid. Table S1. Patient baseline characteristics. Table S2. Trajectories and changes in serum uric acid levels in the two groups. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.